Search results | antibiotic

Reports

Antibiotics Partnering Terms and Agreements

The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in antibiotics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Antibiotics partnering contract documents Top antibiotics deals by value   The Antibiotics Partnering Terms and more »

Insights

Antibiotics partnering analysis in biopharma industry

The  last two years alone has seen $1.9 billion spent on antibiotics partnering by the biopharma industry.

Antibiotics

The term antibiotics was first used in 1942 by Selman Waksman and his collaborator

Cubist Pharmaceuticals – Shaping developments in antibiotics

Cubist Pharmaceuticals is a biopharmaceutical company developing and commercializing medications for acute care in hospitals and surgical environments.

Evolva approached for signing antibiotic biotech deals

The US Defense Threat Reduction Agency  has announced that it has selected Evolva to enter into contract negotiations regarding possible preclinical funding for Evolva’s antibiotic compound GC-072 (the lead compound in Evolva’s EV-035 series)

Both, Actavis and Sanofi competing for Omega Pharma

Several companies are rumored to be competing to acquire Omega Pharma, the fastest growing consumer healthcare company in the U.K. and Ireland.

Pharma and biotech clinical stage partnering – recent trends 2009 to 2014

Partnering trends for the top pharma and biotech companies reviewed with over 2,000 deals analyzed – including summary biopharma deal financials

AstraZeneca and Pfizer in the news for another possible m&a bid

AstraZeneca stock rose two percent to £45.67 pounds yesterday after the Swedish newspaper Dagens Industry suggested another possible Pfizer m&a  bid. AstraZeneca stocks have risen 9.5% in the last week, following a stream of good news regarding its pipeline and takeover bids by Pfizer.

Cubist Pharma, the next acquisition target for big pharmaceuticals

The timing may be right for a takeover of Cubist Pharmaceuticals.

Current Agreements Deal Analysis Update : June 2014

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in May 2014.

The Medicines Company: Competing to become the leader in acute and intensive care treatments

The Medicines Company is a global biopharmaceutical company currently ranked at no.21 in the global biotechnology top 50. The company develops medical solutions for acute and intensive care in hospitals and is aiming to become a leader in this area.

Events

Sorry, your search returned no results.


Deals

AstraZeneca to spin out antibiotics business

AstraZeneca has decided to carve out its early-stage antibiotic research by creating a stand-alone subsidiary company

Collaboration agreement for developing gram-negative antibiotics

Euprotec has entered into an alliance with Cantab Anti-infectives as they seek to develop improved antibiotics to treat multidrug resistant Gram negative bacterial infections.

Asset purchase agreement for topical antibiotics and pain products

Actavis has entered into agreements with Akorn and Hi-Tech Pharmacal to purchase four currently marketed products and one product under development for cash consideration.

Collaborative R&D for Antibiotic Resistance Breakers compounds

Cadila Pharmaceuticals and Helperby Therapeutics have signed a joint agreement on antibiotic drug resistance Research & Development.

Pfizer big pharma deals Sequella for TB antibiotics

Sequella has entered pharma deals with Pfizer, a big pharma company, for the licensing rights to Sutezolid, a tuberculosis antibiotic.

GlaxoSmithKline big pharma deals with DKSH for antibiotics

Big pharma company, GlaxoSmithKline, has signed a pharma deals agreement with DKSH for them to provide contract sales services in both private clinics and trade channel for the big pharma company’s antibiotic product line.

Innovative public-private pharma partnering to tackle antibiotic research

New €224m (£180m) funding to enable development of antibiotics for bacterial infections and drive unprecedented information sharing via public-private pharma partnering initiative

Bayer partners on Trius’ phase III antibiotic in $94m pact

Trius Therapeutics and Bayer have announced they have signed an exclusive agreement to develop and commercialize Trius’ lead Phase 3 antibiotic, torezolid phosphate (torezolid), in China, Japan and all other countries in Asia, Africa, Latin America and the Middle East, excluding North and South Korea.

Rib-X Pharmaceuticals and Sanofi sign research collaboration agreement on novel classes of antibiotics

Rib-X Pharmaceuticals has announced the signature of an exclusive worldwide research collaboration agreement and option for license with Sanofi for novel classes of antibiotics resulting from Rib-X’s RX-04 program for the treatment of resistant Gram-positive and resistant Gram-negative pathogens.

Series A financing for $41 million for Symbiomix

Symbiomix Therapeutics announced multiple milestones, including the closing of the third and final tranche of a $41 million Series A financing and positive results from a multi-center, randomized Phase 2 trial testing a single oral dose of SYM-1219 for the treatment of bacterial vaginosis (BV).